Table 4 Characteristics of the included studies for AUC and trough-guided monitoring
Study | Design of study | Country | Duration of study | Age of patients | Number of patients | Target AUC (mg*hr./L) | Target trough (mg/L) | Rate (%) of MRSA | |
|---|---|---|---|---|---|---|---|---|---|
AUC-guided | Trough-guided | ||||||||
Finch 2017 [47] | Retrospective, quasi-experimental study | America | 2014–2015 | ≥ 18 Mean ± SD: 59.1 ± 16.9 | 734 | 546 | 400–600 | 15–20 | N/A |
Neely 2018 [48] | 3-year, prospective, serial cohort study | America | 2012–2016 | ≥ 18 Mean (range): 48.7 (18–93) | 177 | 75 | 400–800 | 10–20 | 10 |
Meng 2019 [15] | Prospective observational quality assurance study | America | 2017–2018 | ≥ 18 Median ± SD (IQR): Trough-guided 58 ± 17 (46–67) AUC-guided 62 ± 17 (46–68) | 117 | 179 | 400–800 | 10–20 | 9 |
Oda 2020 [49] | Single-centered retrospective study | Japan | 2016–2020 | ≥ 19 Median (range): Trough-guided 68.5 (19–84) AUC-guided 64.0 (19–87) | 22 | 52 | 400–600 | 15–20 | 36 |